[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO OtherControl group: 10 patients receive the standard COVID-19 treatment regimen based on national protocol. The current standard treatment includes antiviral drug Remdesivir, a dose of 200 milligrams on the first day and then 100 milligrams for 5 days, which can be extended to 10 days depending on the clinical condition. The next drug is ReciGen, which is an interferon beta-1 drug. It is given to the patient at a dose of 44 micrograms subcutaneously for 5 days (every other day). The next drug is dexamethasone, which is a glucocorticoid and is given to the patient at a dose of 8 milligrams per day for 10 days. Heparin at a dose of 5000 units subcutaneous 3 times a day, pantoprazole at a dose of 40 milligrams once a day and vitamin C one gram twice a day will be considered for patients.For 14 days, patients are monitored daily for vital signs, electrolytes, blood sugar, liver tests, kidney tests, blood cells, coagulation factors, LDH, inflammatory factors, chest radiographs, and possible gastrointestinal complications. Finally, the two groups are compared in terms of treatment effectiveness and possible side effects of treatment.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: This study is performed in critically ill patients with COVID-19 admitted to Razi Hospital after obtaining informed consent from the patient or their companions.The 10 eligible patients randomly selected will receive the national standard COVID-19 treatment regimen with pentoxifylline. The current standard treatment includes antiviral drug Remdesivir, a dose of 200 milligrams on the first day and then 100 milligrams for 5 days, which can be extended to 10 days depending on the clinical condition. The next drug is ReciGen, which is an interferon beta-1 drug. It is given to the patient at a dose of 44 micrograms subcutaneously for 5 days (every other day). The next drug is dexamethasone, which is a glucocorticoid and is given to the patient at a dose of 8 milligrams per day for 10 days. Heparin at a dose of 5000 units subcutaneous 3 times a day, pantoprazole at a dose of 40 milligrams once a day and vitamin C one gram twice a day will be considered for patients.The dose of pentoxifylline is 400 milligrams, which is determined based on creatinine clearance of the patient as follows: Creatinine clearance above 50 milliliters per minute: three times a day, creatinine clearance 10 to 50 milliliters per minute: twice a day, Creatinine clearance less than 10 milliliters per minute: once daily. The treatment period for patients is 14 days. For 14 days, they will be monitored daily for vital signs, electrolytes, blood sugar, liver tests, kidney tests, blood cells, coagulation factors, LDH, inflammatory factors, chest radiographs, and possible gastrointestinal complications. Finally, the two groups will be compared in terms of treatment effectiveness and possible side effects of treatment.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 971, "treatment_name": "Pentoxifylline", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]